Abriva Plus 400mg/100mg Tablets (28s)

Abriva Plus is a combination medication containing Sofosbuvir and Velpatasvir, formulated to treat chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older. This potent antiviral therapy works by inhibiting viral replication, thereby reducing the viral load in the body. Available for convenient delivery across Pakistan, Abriva Plus offers an effective treatment option for those affected by HCV.

The dual-action mechanism of Sofosbuvir and Velpatasvir targets multiple stages of the hepatitis C virus lifecycle, leading to improved treatment outcomes. This combination therapy is known for its high efficacy rates, often resulting in sustained virologic response (SVR) in patients. The simplified dosing regimen enhances patient adherence, making it easier to achieve optimal results in HCV management.

For adults and children over 3 years, the recommended dosage is one tablet of Abriva Plus taken orally once daily, with or without food. It is important to follow the prescribed treatment duration as directed by a healthcare professional, which typically ranges from 8 to 24 weeks depending on the specific genotype and treatment history of the patient. It is advised to swallow the tablet whole without crushing or chewing.

Abriva Plus can be taken with or without food, which provides flexibility in administration. However, it is advisable to avoid taking the medication with antacids containing aluminum or magnesium within 4 hours of administration, as these can affect the absorption of the active ingredients. Additionally, patients should refrain from consuming alcohol during treatment to minimize liver strain.

The safety of Abriva Plus during pregnancy and breastfeeding has not been fully established. Women who are pregnant or planning to become pregnant should consult their healthcare provider before starting treatment. It is recommended that women use effective contraception during therapy and for a period after completion. Breastfeeding mothers should also seek medical advice, as the drug's effects on nursing infants are not well-documented.

Precautions

Patients should inform their healthcare provider about any pre-existing liver conditions, particularly cirrhosis, as this may influence treatment decisions. Regular monitoring of liver function and viral load is essential throughout the treatment course. Abriva Plus should be used cautiously in patients with a history of significant drug interactions or those taking other antiviral medications.

Adverse Effects

Common side effects of Abriva Plus may include fatigue, headache, nausea, and insomnia. While most patients tolerate the medication well, some may experience more severe reactions such as jaundice, dark urine, or unusual bleeding. Any persistent or severe side effects should be reported to a healthcare professional immediately for further evaluation.

Abriva Plus is contraindicated in patients with a known hypersensitivity to Sofosbuvir, Velpatasvir, or any of the inactive ingredients in the formulation. It should not be used in combination with certain other medications that may lead to severe interactions. A thorough medical history should be reviewed to ensure safe and effective use of this antiviral therapy.